www.alk.net
  • Your allergy
    • What is allergy
      • House dust mite allergy
      • Pollen allergy
      • Living with allergy
      • Socio-economic impact
    • What is allergic asthma
    • How is allergy diagnosed
    • Treating allergy
  • Our solutions
    • Consumer healthcare
    • Diagnostics
    • Allergy vaccines
      • Production
    • Emergency medicine
  • Our science
    • Scientific focus
    • Science & technology
    • Pipeline
    • Digital innovation
    • Clinical data sharing
    • Collaboration & partnerships
    • Healthcare Professionals
      • Allergy Immunotherapy
      • Reweal
      • Clinical trials
      • Webinars
      • The Henning Lowenstein Research Award
  • Our company
    • Press
    • Our strategy
    • Our leadership
    • Our history
    • Corporate governance
  • Sustainability
  • Investors
    • Overview
    • Financial reporting
      • Risk management
      • Reporting standards
      • Auditors
    • Governance
      • Executive Leadership Team
      • Board of Directors
    • News & Events
      • Company Releases
      • Company releases (DK)
      • Webcasts & presentations
      • Investor calendar
      • Capital Markets Day 2024
    • The Share
      • Dividend history
      • Analyst coverage
      • Analyst estimates
      • Shareholder information
      • Authorizations
    • Contact IR
    • Annual general meeting
      • Annual general meeting (DK)
    • Capital Markets Day 2024
  • Careers
    • Working at ALK
    • Vacant positions
    • Cultural Beliefs
  • Select country
Search

News release

Links: 
Company Releases
Company releases (DK)
Webcasts & presentations
Investor calendar
Capital Markets Day 2024

« Back

Disease-modifying effect of GRAZAX® verified

February 08, 2010

PDF Version

Supporting Materials:
fm-01-10-uk.pdf
ALK releases its annual report 2009 on Tuesday, February 23, 2010.

The company therefore invites analysts and investors to a meeting with
Management on Wednesday, February 24, at 09.00 a.m. at Heerings Gaard,
Overgaden neden Vandet 11, 0900 Copenhagen C, at Nordea. Breakfast is served
from 08.30 a.m. 

Please contact events@nordea.com or tel. +45 33 33 25 38, if you wish to
participate. 

The meeting will be held in English and webcast live on www.alk-abello.com. It
will be possible to call in with questions. 

Participants in the conference call are kindly requested to call in before 8.55
a.m. (CET). Danish participants should call in on tel +45 7026 5040 or +45 3271
4767 and international participants should call in on tel +44 208 817 9301. 


ALK-Abelló A/S


Jens Bager


For further information please contact:

Investor Relations: Per Plotnikof, tel +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tlf. + 45 4574 7901, mobile + 45 2064 1143
  • Email Alerts

    Email Alerts

  • Downloads

    Downloads

  • RSS

    RSS

  • Print

    Print

  • Share

    Share

  • English

    English

  • Search

    Search




Select Country Menu

  • Change Country

Quick Links

  • Contact us
  • News
  • Media
  • Vacant jobs
  • Products

ALK Footer Copyright Text

ALK-Abelló A/S ∙ Bøge Allé 6 ∙ DK-2970 Hørsholm ∙ Denmark ∙ CVR no. 63717916 ∙ T +45 45 74 75 76 Legal disclaimer © ALK ∙ All rights reserved